Susquehanna International Group
VYGR icon

Susquehanna International Group’s Voyager Therapeutics VYGR Stock Holding History

Susquehanna International Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.5K Sell
14,700
-20,700
-58% -$78.5K ﹤0.01% 12816
2026
Q1 		$137K Buy
35,400
+19,900
+128% +$78.3K ﹤0.01% 12105
2025
Q4 		$60.9K Sell
15,500
-700
-4% -$3.1K ﹤0.01% 11686
2025
Q3 		$75.7K Sell
16,200
-6,500
-29% -$23.5K ﹤0.01% 11705
2025
Q2 		$70.6K Buy
+22,700
New +$73.2K ﹤0.01% 11986
2025
Q1 		– Sell
-37,400
Closed -$212K – 13557
2024
Q4 		$212K Buy
37,400
+11,600
+45% +$74.8K ﹤0.01% 10609
2024
Q3 		$151K Buy
25,800
+5,400
+26% +$39.3K ﹤0.01% 10738
2024
Q2 		$161K Sell
20,400
-16,500
-45% -$138K ﹤0.01% 10612
2024
Q1 		$344K Buy
36,900
+19,600
+113% +$165K ﹤0.01% 9394
2023
Q4 		$146K Sell
17,300
-40,800
-70% -$296K ﹤0.01% 11001
2023
Q3 		$450K Buy
58,100
+31,100
+115% +$284K ﹤0.01% 8482
2023
Q2 		$309K Sell
27,000
-131,000
-83% -$1.36M ﹤0.01% 9374
2023
Q1 		$1.22M Buy
+158,000
New +$1.26M ﹤0.01% 6295
2022
Q4 		– Sell
-55,300
Closed -$327K – 13805
2022
Q3 		$327K Sell
55,300
-15,500
-22% -$99.2K ﹤0.01% 9574
2022
Q2 		$418K Sell
70,800
-6,900
-9% -$46.6K ﹤0.01% 8715
2022
Q1 		$592K Sell
77,700
-27,400
-26% -$122K ﹤0.01% 8535
2021
Q4 		$285K Buy
105,100
+86,300
+459% +$294K ﹤0.01% 10610
2021
Q3 		$49K Sell
18,800
-26,600
-59% -$86.4K ﹤0.01% 12355
2021
Q2 		$188K Sell
45,400
-106,500
-70% -$483K ﹤0.01% 11658
2021
Q1 		$715K Buy
151,900
+74,700
+97% +$509K ﹤0.01% 8603
2020
Q4 		$552K Buy
+77,200
New +$742K ﹤0.01% 8068
2019
Q3 		– Sell
-21,700
Closed -$591K – 10915
2019
Q2 		$591K Buy
21,700
+6,000
+38% +$137K ﹤0.01% 6928
2019
Q1 		$300K Buy
+15,700
New +$205K ﹤0.01% 7214
2018
Q4 		– Sell
-27,700
Closed -$524K – 10076
2018
Q3 		$524K Sell
27,700
-6,300
-19% -$121K ﹤0.01% 6430
2018
Q2 		$664K Sell
34,000
-34,300
-50% -$678K ﹤0.01% 6235
2018
Q1 		$1.28M Buy
68,300
+1,900
+3% +$41.1K ﹤0.01% 4734
2017
Q4 		$1.1M Buy
+66,400
New +$1.14M ﹤0.01% 5028

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Susquehanna International Group's VYGR Position: Q2 2026 in Review

Susquehanna International Group increased its Voyager Therapeutics (VYGR) stake by 15% in Q2 2026, buying an estimated $45.5K and bringing the position to 90,899 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #10912.

Susquehanna International Group first reported a position in VYGR in Q4 2016 and has held it in 32 quarters since. The position peaked at $2.48M in Q1 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Susquehanna International Group held 90,899 shares of Voyager Therapeutics worth $318K as of Q2 2026.
  • Susquehanna International Group bought 12,008 Voyager Therapeutics shares in Q2 2026, an estimated $45.5K.
  • Voyager Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #10912 holding.
  • Susquehanna International Group first reported a position in Voyager Therapeutics in Q4 2016 and has held it in 32 quarters since.
  • Susquehanna International Group's Voyager Therapeutics position peaked at $2.48M in Q1 2023.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.